LGALS3 and inflammatory bowel disease: As outlined above (see Section 5), galectin-3 may play a protective role in IBD [142,177], and the increased galectin-3 levels observed in PSC-IBD patients [148] could potentially contribute to the milder manifestations of IBD frequently noted in this group [29].